The modulation of serotonin (5-HT) release by opioid receptors in the hippocampus of the awake, unrestrained rat was evaluated by use of in vivo microdialysis. The hippocampus was perfused with Ringer's solution (2/~l/min), and extracellular levels of 5-HT and its major metabolite, 5-hydroxyindoleacetic acid (5-HIAA) were estimated by assaying their concentration in the dialysate by HPLC-ECD. Addition of potassium (K ÷, 60 and 120 mM) to the perfusate evoked a concentration-dependent release of 5-HT, but did not alter extracellular 5-HIAA levels. Co-perfusion of morphine (0.1 to 10 ~M) with K + (120 mM) produced a concentration-dependent reduction of 5-HT release. Naltrexone (0.03 to 3 mg/kg, i.p.), a relatively selective/z-opioid receptor antagonist, blocked in a dose-dependent manner the morphine (10/zM)-induced inhibition of 5-HT release. Naltrexone alone did not alter significantly either extracellular 5-HT levels or the release of 5-HT evoked by K +. Neither co-perfusion with [D-Pen 2, D-PenS]-enkephalin (DPDPE, 1 to 10 /zM), an agonist selective for 8-opioid receptors, nor with U-69593 (10 /zM), an agonist selective for K-opioid receptors, modified the K + (120 mM)-evoked release of 5-HT. These findings indicate that p~-opioid receptors modulate the physiological release of 5-HT from serotonergic neurons in the rat hippocampus.
INTRODUCTION
Specific opioid receptors appear to modulate the release of specific neurotransmitter substances in the central nervous system. For example, stimulation of ~-opioid receptors inhibits both K÷-stimulated and electrically stimulated release of [3H]dopamine from rat striatal slices, but does not inhibit the release of [taC]acetylcholinetS'16't9. In contrast, stimulation of Kopioid receptors in rat striatal slices inhibits the neuronal release of [taC]acetylcholine, but not that of [3H]dopamine. In rat cerebral cortical slices, neuronal release of [3H]norepinephrine has been shown to be modulated by/x-opioid receptors 16'19 .
The role of opioid receptors in the regulation of serotonin (5-HT) release, however, remains unclear at this time. Hagan and Hughes 6 reported that opioid receptors were not involved in the electrically stimulated release of [3H]5-HT from rat cortical slices. Dewar et al. 3 also were unable to demonstrate opioid receptor mediation of K÷-stimulated release of [3H]5-HT from slices of rat globus pallidus. In contrast, Passarelli and Costa t7 reported that stimulation of/z-, 3-and ~c-opioid receptors in rat hippocampal slices inhibited K÷-stimulated release of [3H]5-HT. In this latter study, [D-Ala 2, N-Me-Phe 4, GlyS-ol]enkephalin (DAMGO), a /z-opioid receptor agonist, and DPDPE, ~-opioid receptor agonist, were more efficacious than U50488H ( trans-3,4-dichloro-N-methyl-N- [2- (1-pyrrolidinyl)-cyclohexyl]benzene-actamine), a K-opioid receptor agonist, as inhibitors of [3H]5-HT release. All of these studies have involved the use of in vitro preparations, and the results of such studies might be influenced significantly by the nature of the artificial environment in which they must be conducted.
In vivo microdialysis, in combination with high performance liquid chromatography (HPLC) and electrochemical detection (ECD) , permits the study of neuro- In addition, the actions of naltrexone, an antagonist similar to naloxone in its selectivity for/z-opioid receptors, was studied.
MATERIALS AND METHODS

Animals
The experiments were performed on male, Wistar rats (250-350 g and 8 to 12 weeks old, Shizuoka Laboratory Animal Center, Hamamatsu, Japan). The animals were housed in a room with a 12-h light (07.00-19.00)-dark (19.00-07.00) cycle and were given free access to food and water.
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Brain microdialysis
Rats were anesthetized with ketamine (100 mg/kg, i.p.), and an 8-mm dialysis-probe guide cannula was stereotaxically implanted into the hippocampus so that a concentric dialysis probe with a 3-mm tip would be positioned with its tip at the following co-ordinates with relation to the bregma and dural surface of the brain18: rostral-caudal, -5.8 mm; lateral -4.8 mm. ventral -7.0 mm, from the bregma and the dural surface. The guide cannula was attached to the skull with dental cement. Two days after the surgical implantation of the guide cannula, a dialysis probe was inserted into the guide cannula and the probe was then perfused continuously (2 p.l/min) with Ringer's solution of the following composition (raM): NaCl 147, KCI 4, CaCl 2 2.3, pH 6.4. The perfusion medium was delivered by a 1-ml syringe mounted on a microinfusion pump (CMA/100, Carnegie Medicin, Stockholm, Sweden) through a coiled teflon tube and returned through a similar coiled teflon tube that allows the rat to move about freely. In preliminary experiments it was found that the levels of 5-HT in the dialysate were high immediately after insertion of the probe but decreased to constant values within 3 h. Therefore, collection of the perfusate was started 3 h after implantation of the probe. Nine successive 40-~1 samples were collected at 20-min intervals in vials that contained 10 ~l of ice-cold acetic acid (0.05 N). The samples were injected immediately into a high performance liquid chromatograph.
To stimulate 5-HT release, KCl (either in a concentration of 60 or 120 mM) was administered through the perfusion system for two 10-min periods of time. In order to maintain the osmolarity of the perfusion fluid when either 60 or 120 mM KCI was added, the existing NaC1 was replaced with the KCI. The first administration of KCI (S1, 40-50 min, Figs. 2 and 3) occurred at the beginning of the fourth 20-min collection period and the second administration at the beginning of the seventh ($2, 100-110 min, Figs. 2 and 3) collection period. In control experiments, the S 2/S 1 ratio was found to be approximately 1.0 under these experimental conditions. Morphine and other opioid receptor agonists were added to the perfusion solution at the time of the second administration of KC1 ($2). Naltrexone, an opioid receptor antagonist, was injected intraperitoneally 20 min prior to the second KCl-perfusion period ($2). At the end of each experiment, the rat was sacrificed, and its brain was removed, sectioned and examined histologically to determine the precise insertion site of the dialysis probe.
Determination of 5-HT and 5-HIAA
5-HT and its metabolite, 5-HIAA, were separated and measured by use of a HPLC system coupled to an ECD system as described previously hi. The HPLC-ECD system consisted of a pump (P-500, Irika Kogyo, Kyoto, Japan) coupled to a reversed-phase column (EiCOM, MA-50DS, ODS, 5/*m particle size) and an electrochemical detector (Irika, E-502). Shown in Fig. 1 are typical chromatograms obtained with samples of dialysate collected before (Fig.  1A ) and after the administration of KCI, 120 raM, (Fig. 1B) or after the simultaneous administration of KCI, 120 mM, and morphine, 1 ~M, (Fig. 1C) . Note that morphine produces a peak that does not overlap with those peaks produced by either 5-HT or 5-HIAA.
Drugs
The following compounds were used: 5-hydroxytryptamine creatinine sulphate (Sigma Chemical Co. Ltd., St. Louis, MO, USA), morphine sulphate (Takeda Pharmaceutical Co., Osaka, Japan), naltrexone hydrochloride (DuPont Pharmaceuticals, Garden City, NY, USA), [D-Pen 2, o-Pen-S]-enkephalin (Sigma), U-69593 (The Upjohn Co., Kalamazoo, MI, USA). and ketamine hydrochloride (Sankyo Co. Ltd., Tokyo, Japan).
Calculations and statistical analysis
5-HT in dialysates is expressed as a percentage of the absolute amount of 5-HT in the dialysate collected during the third 20-min collection period, i.e. the period immediately before addition of KCI to the perfusate. The amount of 5-HT released during K + stimulation is expressed as the amount in the dialysate collected during the fourth collection period (S 1) less the average of the amounts collected during the third and fifth collection periods or the amount collected during the seventh collection period (S 2) less the average of the amounts collected during the sixth and eighth collection periods. In vitro recoveries for some microdialysis probes were measured in order to determine the recovery efficiency of the probe membranes. To measure recovery, probes were placed in Ringer's solution that contained both 5-HT, 100 pg//xl, and 5-HIAA, 100 pg//zl, and perfused at a flow rate of 2/zl/min at 37+ 1 °C. Mean in vitro recoveries (the concentrations of the 5-HT or 5-HIAA in the dialysate expressed as a percentage of the concentrations of these compounds outside of the dialysis probe)+S.E.M, of 8 determinations were 14.9_+ 2.7% for 5-HT and 11.7_+ 1.9% for 5-HIAA.
All results are given as means+_S.E.M. Statistical comparisons were carried out using analysis of variance followed by Student's t-test. Values of P less than 5% were considered significant.
RESULTS
Effect of K + on 5-HT release
When introduced into the perfusion buffer, KCI increased the concentration in the dialysate of 5-HT, but not that of 5-HIAA, in a concentration-dependent manner (Fig. 2) . The mean basal output of 5-HT from serotonergic neurons in the rat hippocampus was 18.0 
Effect of opioid agonists on K +-evoked 5-HT release in the hippocampus
Morphine, but not DPDPE or U-69593, inhibited the K+-induced release of 5-HT when added to the (Table I) . 
TABLE I
Effects of DPDPE and U69593 on the K +-evoked release of 5-HT
The opioid agonist was administered simultaneously with the second administration of KCI ($2). Each value represents the mean of n experiments _+ S.E.M. Similarly, U-69593, an agonist highly selective for Kopioid receptors, caused no inhibition of release when co-perfused with KC1 at the high concentration of 10 t~M during S 2 (Table I) . None of the three agonists, when administered without the concomitant administration of KCI, altered the spontaneous release of 5-HT. These results suggest that the modulation by opioids of neuronal 5-HT release in the rat hippocampus is mediated solely by/z-opioid receptors.
Experimental group Ratio (S 2/S 1) n
Antagonism by naltrexone of the morphine-induced inhibition of 5-HT release
To determine further whether the inhibitory actions of morphine on 5-HT release were mediated by opioid receptors, the actions of morphine were determined in rats treated with naltrexone, an opioid antagonist relatively selective for /.L-opioid receptors, in doses that ranged from 0.03 to 3 mg/kg. No concentration of naltrexone caused a change in the release of 5-HT during the period immediately prior to the co-perfusion of morphine with KCI ($2). Pretreatment with naltrexone did, however, prevent the inhibition of 5-HT release by morphine, 10 /zM, in a concentration-dependent manner (Figs. 3 (solid triangles) and 4B) . The response to morphine was almost completely blocked by naltrexone, 3 mg/kg. These observations are consistent with the hypothesis that morphine inhibits hippocampa! 5-HT release by acting at a /z-opioid receptor.
DISCUSSION
In the present study K + evoked large increases in extracellular 5-HT levels in the hippocampus of awake, unrestrained rats that were reflected by increased concentrations of 5-HT in the dialysate during in vivo microdialysis. These increases in 5-HT were related to the concentration of KCI in the perfusion medium. During in vivo microdialysis of the hippocampus of chloralose-anesthetized rats, Sharp et al. 2° found similar increases in extracellular 5-HT levels in the rat hippocampus during electrical stimulation of the dorsal raphe nucleus. They demonstrated a good correlation between the frequency of electrical stimulation and the amount of 5-HT in the dialysate. These changes in 5-HT levels were accompanied by small increases in the levels of 5-HIAA, the major metabolite of 5-HT in the brain, in the dialysates. 5-HIAA levels, however, were not correlated with the frequency of dorsal raphe nucleus stimulation or with 5-HT levels in the perfusates. No changes in 5-HIAA levels occurred with K + stimulation of serotonergic neurons in the rat hippocampus in the present study despite large increases in 5-HT levels. These findings are consistent with the hypothesis that 5-HIAA levels reflect the turnover of the total 5-HT pool in the brain rather than the stimulated release of neuronal 5-HT 5'7.
The action of morphine and other opioid agonists upon 5-HT release and upon 5-HIAA levels in various areas of the rat central nervous system is quite complex. A number of studies have suggested that either acute or chronic administration of morphine increases 5-HT release and turnover in the rat brain 4'21'23. Matos et al. 9A° have reported that systemic administration of morphine has highly variable effects upon extracellular levels of 5-HT in the dorsal spinal cord as measured by in vivo microdialysis. These investigators reported that the systemic administration of morphine increased 5-HT levels in only half of the rats studied and that DAMGO, administered intracerebroventricularly, increased 5-HT levels in only one third of the animals. They also found that 5-HIAA levels either decreased or remained unchanged after morphine administration. In contrast, Wood 22 found that morphine caused marked increase in the 5-HIAA content of the dorsal spinal cord. This action of morphine was dose-dependent and was antagonized by naioxone. This effect of morphine, however, was not shared by other opioid agonists that were known to stimulate either ~-or K-opioid receptors. The present study and a previous study 17 both found that opioid agonists inhibited the release of 5-HT during stimulation of serotonergic neurons in the rat hippocampus. Our study also found no effect of opioid agonists or of naltrexone upon hippocampal extracellular 5-HIAA levels.
The present study suggests that /z-opioid receptors modulate K+-evoked release of 5-HT from serotonergic neurons in the rat hippocampus as determined by in vivo microdialysis. Morphine produced a concentration-dependent inhibition of 5-HT release; and this action was antagonized by naltrexone, an antagonist relatively selective for ~-opioid receptors. Naltrexone alone had no effect upon the spontaneous release of 5-HT which suggests that endogenous opioids do not exert a tonic regulation of 5-HT release under resting conditions.
Autoradiographic studies have demonstrated the presence of binding sites for ligands relatively selective for 6-and K-opioid receptor sites, as well as binding sites for ~-opioid receptor-selective ligands, in the rat hippocampus 2,s. According to these reports, /z-opioid receptors predominate in this area of the rat brain, although 6-and K-opioid receptors are also present. In the present study, DPDPE, a 6-opioid receptor-selective agonist, and U-69593, a K-opioid receptor-selective agonist, did not modify K+-evoked 5-HT release from neurons in the rat hippocampus even when administered in concentrations considerably higher than those required to produce maximum effects in other systems. Thus, despite the presence of 6-and K-opioid receptor binding sites in the rat hippocampus, the /z-opioid receptor would appear to be the primary opioid receptor involved in the regulation of 5-HT release in the rat hippocampus in vivo.
Several investigators have reported that 5-HT release is not modulated by opioid receptors in the rat brain. Hagen and Hughes 6 found the opioid agonists did not modify the electrically stimulated release of [3H]5-HT from rat cerebral cortical slices; and Dewar et al. 3 reported that opioid agonists did not modify K+-evoked release of 5-HT from slices of the rat globus pallidus. The differences between these observations and those of the present study might depend upon the areas of the brain that were studied. A similar regional difference in the regulation of 5-HT release by dopamine has been found. Benkirane et al. ~ reported that dopamine, through stimulation of a D I receptor, regulates the release of [3H]5-HT from neurons in the substantia nigra but not from neurons in the hippocampus. These investigators also reported no effect of opioid agonists upon [3H]5-HT release in the substantia nigra.
In contrast to the present study, Passarelli and Costa ~v reported that/~-, 3-and K-agonists inhibited to various degrees the release of [3H]5-HT from slices of rat hippocampus. The effects of DAMGO in their study were those of a typical/z-opioid receptor agonist in that they were blocked competitively by naloxone. The modulation by DPDPE of [3H]5-HT release was unusual, however, in that naloxone produced a noncompetitive antagonism of the inhibitory action of that drug. U-50488H, a K-opioid receptor-selective agonist, produced a small inhibition of K+-evoked [3H]5-HT release that was reversed by naloxone. The differences between the present study and that of Passarelli and Costa iv might be a result of differences in experimental approach. In the in vitro brain slice study, the concen- 
